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SUPPLEMENTARY METHODS   
 
INCLUSION/EXCLUSION CRITERIA FOR INDIVIDUAL COHORTS 
Milan cohort  
Inclusion criteria: 
Pneumonia was defined as the presence of a new pulmonary infiltrate on chest 
radiograph at the time of hospitalization associated with 1 of the following: (1) new 
or increased cough with/without sputum production; (2) fever (>37.8oC) or 
hypothermia (<35.6oC); or (3) abnormal white blood cell count (either leukocytosis 
or leukopenia), or C-reactive protein values above the local upper limit. 
Exclusion criteria:  
Hospitalisation within 15 days prior to admission 
 
FAILCAP cohort 
Inclusion criteria: 
1. New pulmonary infiltrate seen on chest radiograph or CT Scan of the chest within 
48 hours after hospitalization. (The finding of infiltrate by chest radiograph or other 
imaging technique is "required" for the diagnosis of pneumonia, according to the 
2007 consensus guidelines from the Infectious Diseases Society of America and the 
American Thoracic Society (2). Patients identified during the screening process will 
be enrolled if a chest radiograph or CT Scan of the chest taken within 48 hours after 
hospital admission revealed a new infiltrate consistent with pneumonia 
plus at least one of the following: 
2. New or increased cough with/without sputum production          
3. Fever (documented temperature -rectal or oral- >37.8o C) or hypothermia 
(documented temperature –rectal or oral- <35.6o C 
4. Abnormal white blood cell count, either leukocytosis (>10,000/cm3) or leucopenia 
(< 4,000/cm3) 
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Exclusion criteria: 
Patients who meet at least one of the following definitions will be excluded from the 
analysis: 
 
1)    Patient has hospital-acquired pneumonia, defined as pneumonia that develops 
after 48 hours of the current hospitalization, or pneumonia that develops in a 
patient who had been discharged from the hospital within the prior 14 days of the 
current hospitalization. 
2)    Patient is re-admitted with a new episode of pneumonia during the 30-day 
follow up period. 
3)    Unstable psychiatric or psychological condition rendering the subject unlikely to 
be cooperative or to complete the study requirements. 
4)    Subject history that in the investigator’s opinion would preclude subject 
compliance with the protocol.  
 
Edinburgh cohort 
Inclusion criteria: 
Patients were included in the study if they presented with a new infiltrate on chest 
radiograph and had 3 or more of the following symptoms or signs (cough, sputum 
production, breathlessness, pleuritic chest pain or signs consistent with pneumonia 
on auscultation).   
 
Exclusion criteria:  
Hospital-acquired pneumonia (development of symptoms >48 hours following 
admission or discharge from an acute care facility <2 weeks prior to admission); 
active thoracic malignancy; immunosuppression (defined as current (>28 day) use of 
oral prednisolone at any dose or other immunosuppressive drugs (methotrexate, 
azathioprine, cyclosporin and anti-tumour necrosis factor alpha agents)  or patients 
with solid organ transplantation); pulmonary embolism and patients in whom active 
treatment was not considered appropriate (palliative care). 
 
Barcelona cohort  
Inclusion criteria: 
Adult patients (>18 years) presenting with pneumonia, defined as the presence of a 
new infiltrate on a chest radiograph together with clinical symptoms that were 
suggestive of lower respiratory tract infection (e.g. fever, cough, sputum production, 
pleuritic chest pain). 
 
Exclusion criteria: 
1) patients without a positive microbiologic diagnosis, 2) severe immunosuppression 
(AIDS, chemotherapy, immunosuppressive drugs [e.g., oral corticosteroid ≥10 mg 
prednisone or equivalent per day for at least two weeks]), 3) health care-associated 
pneumonia cases, 4) active tuberculosis, 5) patients with cystic fibrosis, and 6) cases 
with a confirmed alternate diagnosis 
 
Microbiological testing for atypical pathogens 
Milan and FAILCAP cohorts: 
PCR based identification  
Nested PCR with primers amplifying 207-bp fragment of major outer member 
protein genes (ompA) of Chlamydia pneumoniae, 104-bp fragment P1 protein 
antigen of Mycoplasma pneumoniae and 403-bp fragment of the macrophage 
infectivity potentiator protein (MIP) of Legionella pneumophila were used.After 
amplification, 4% agarose gel electrophoresis and sybr safe DNA stain were used to 
visualise the PCR products.  
 
Serology:  
Chlamydia pneumoniae: the presence of serum antibodies (IgG, IgA, IgM) was 
determined by the ANI Labsystems  microimmunofluorescence (MIF) test. The serum 
samples were considered positive when there were titers of  >1:64 for IgG antibodies 
and >1:16 for IgA and IgM.  
Mycoplasma pneumoniae: the detection of serum antibodies (IgG, IgM) was 
determined by an enzyme-linked immunosorbent assay (ELISA)  (Viro-Immun Labor –
Diagnostika GmbH). 
 
Edinburgh cohort: 
Testing for atypical pathogens (urine testing for Legionella and PCR based testing for 
M. pneumoniae and C. pneumoniae) was conducted in accordance with the British 
Thoracic Society/NICE guidelines, as previously reported9. 
 
Barcelona cohort:  
Blood samples for serology of atypical pathogens  were performed at admission and 
within the third and sixth week thereafter. The etiology was considered definite if 
the following criteria was met:1) elevated serum levels of IgM against C. pneumoniae 
(≥1:64), C. burnetii (≥1:80) and M. pneumoniae (any positive titre) 2) seroconversion 
(ie, a fourfold increase in IgG titres) for C. pneumoniae and L. pneumophila >1:128, C. 
burnetii >1:80 
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